X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
ALEMBIC PHARMA Fact Sheet, ALEMBIC PHARMA Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA Fact Sheet   (APLL)

Here is the latest financial fact sheet of ALEMBIC PHARMA. For more details, see the ALEMBIC PHARMA quarterly results and ALEMBIC PHARMA share price and chart. For a sector overview, read our pharmaceuticals sector report.

ALEMBIC PHARMA Price History

Price Rs 571.4
Mkt Cap Rs m 107,711
Vol '000 3.4
P/E X 29.5
P/CF X 13.6
EPS (TTM) Rs 19.4
% ch % 3.3
No. of shares m 188.52
% ch week % 2.3
% ch 1-mth % 4.2
% ch 12-mth % -1.9
52 week H/L Rs 709.3/469.8
(As on Feb 20, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

ALEMBIC PHARMA Financials

No. of Mths
Year Ending
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
5-Yr Chart
Click to enlarge
ALEMBIC PHARMA EQUITY SHARE DATA
High Rs51113310495792 
Low Rs3448103228443 
Sales per share (Unadj.) Rs77.780.698.8109.1167.0 
Earnings per share (Unadj.) Rs6.98.812.515.038.2 
Diluted earnings per shareRs6.98.812.515.038.2 
Cash flow per share (Unadj.) Rs8.710.614.617.442.0 
Dividends per share (Unadj.) Rs1.402.503.003.504.00 
Adj. dividends per shareRs1.402.503.003.504.00 
Dividend yield (eoy) %3.33.11.51.00.6 
Book value per share (Unadj.) Rs21.026.735.846.984.9 
Adj. book value per shareRs21.026.735.846.984.9 
Shares outstanding (eoy) m188.52188.52188.52188.52188.52 
Bonus/Rights/Conversions  ----- 
Price / Sales ratio x0.51.02.13.33.7 
Avg P/E ratio x6.29.116.524.116.2 
P/CF ratio (eoy) x4.97.614.120.814.7 
Price / Book Value ratio x2.03.05.87.77.3 
Dividend payout %20.328.524.023.310.5 
Avg Mkt Cap Rs m8,01215,11938,93968,122116,383 
No. of employees `000NANANANANA 
Total wages/salary Rs m1,6851,9382,4703,0684,214 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
ALEMBIC PHARMA INCOME DATA
Net Sales Rs m14,65415,20418,63220,56131,487 
Other income Rs m1439322355 
Total revenues Rs m14,66815,24318,66420,58431,542 
Gross profit Rs m2,1942,5203,5774,03010,060 
Depreciation Rs m337350405444722 
Interest Rs m262146981837 
Profit before tax Rs m1,6102,0643,1063,5919,356 
Minority Interest Rs m00000 
Prior Period Items Rs m0002-2 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m3094117517642,160 
Profit after tax Rs m1,3011,6532,3552,8297,194 
Gross profit margin %15.016.619.219.631.9 
Effective tax rate %19.219.924.221.323.1 
Net profit margin %8.910.912.613.822.8 
ALEMBIC PHARMA BALANCE SHEET DATA
Current assets Rs m6,8766,3227,0158,90715,066 
Current liabilities Rs m5,3494,4164,4746,8417,674 
Net working cap to sales %10.412.513.610.123.5 
Current ratio x1.31.41.61.32.0 
Inventory Days Days6464616867 
Debtors Days Days5056546441 
Net fixed assets Rs m3,2613,7654,1765,9478,237 
Share capital Rs m377377377377377 
"Free" reserves Rs m3,2034,5826,2358,37415,416 
Net worth Rs m3,9505,0296,7568,84616,005 
Long term debt Rs m9497055221880 
Total assets Rs m10,51910,47812,17316,41224,594 
Interest coverage x7.115.232.7202.7255.2 
Debt to equity ratio x0.20.10.100 
Sales to assets ratio x1.41.51.51.31.3 
Return on assets %14.917.220.217.329.4 
Return on equity %32.932.934.932.044.9 
Return on capital %38.238.544.040.058.7 
Exports to sales %31.930.640.339.355.7 
Imports to sales %12.510.29.510.010.4 
Exports (fob) Rs m4,6804,6507,5028,08517,551 
Imports (cif) Rs m1,8321,5541,7652,0503,283 
Fx inflow Rs m4,7964,8027,7208,28417,811 
Fx outflow Rs m2,2752,1992,6283,1475,318 
Net fx Rs m2,5212,6035,0925,13712,493 
ALEMBIC PHARMA CASH FLOW
From Operations Rs m 1,418 2,648 2,400 1,718 9,304 
From Investments Rs m -564 -670 -811 -2,556 -3,105 
From Financial Activity Rs m -446 -2,288 -1,511 867 -1,959 
Net Cashflow Rs m 408 -310 79 29 4,240 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 74.1%
Foreign collaborators 0.0%
Indian inst/Mut Fund 2.9%
FIIs 9.1%
ADR/GDR 0.0%
Free float 13.9%
Shareholders 49,328
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF Alembic Road, ,Vadodara,Gujarat - 390 003
E-MAIL apl.investors@alembic.co.in WEB www.alembic-india.com
TELEPHONE (0265) 2282 550 FAX (0265) 2282 506
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, B-102-103, Shangrila Complex, Akota, Vadodara-20
AUDITOR K. S. Aiyar & Co.
CHM: Chirayu R. Amin (MD) COMP SEC: Rajkumar Baheti YEAR OF INC: 2010 BSE CODE: 533573 FV (Rs): 2 DIV YIELD (%): 0.7

More Pharmaceuticals Company Fact Sheets:   AMAR REMEDIES  AJANTA PHARMA  STRIDES SHASUN LTD  DISHMAN PHARMA  WYETH LTD  

Compare ALEMBIC PHARMA With:   AMAR REMEDIES  AJANTA PHARMA  STRIDES SHASUN LTD  DISHMAN PHARMA  WYETH LTD  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Marginally Lower; Capital Goods & Realty Stocks Fall(Closing)

Indian share markets witnessed selling pressure in the final hour of trade to finish just below the dotted line. At the closing bell, the BSE Sensex closed lower by 71 points.

Views on news

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA - IPCA LABS COMPARISON

COMPARE ALEMBIC PHARMA WITH

MARKET STATS